GLP-1 receptor agonist therapy does not increase the risk of thyroid tumors in people with type 2 diabetes, according to a study in the journal Diabetes Care. The retrospective study, which included data from several international databases, found no increased risk of both malignant and benign thyroid tumors with GLP-1 RAs compared with other second-line therapies.
Full Story: Endocrinology Advisor (7/7)